Dr. Reddys Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif, in the United States
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, expanding its oncology portfolio and...